Protocol

RNA Vaccines

Volume 1499 of the series Methods in Molecular Biology pp 223-236

Date:

Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome

  • Mustafa DikenAffiliated withTRON – Translational Oncology at the University Medical Center, Johannes Gutenberg UniversityBiopharmaceutical New Technologies (BioNTech) Corporation
  • , Mathias VormehrAffiliated withBiopharmaceutical New Technologies (BioNTech) CorporationResearch Center for Immunotherapy (FZI)
  • , Christian GrunwitzAffiliated withBiopharmaceutical New Technologies (BioNTech) CorporationResearch Center for Immunotherapy (FZI)
  • , Sebastian KreiterAffiliated withTRON – Translational Oncology at the University Medical Center, Johannes Gutenberg UniversityBiopharmaceutical New Technologies (BioNTech) Corporation
  • , Özlem TüreciAffiliated withTRON – Translational Oncology at the University Medical Center, Johannes Gutenberg University
  • , Ugur SahinAffiliated withTRON – Translational Oncology at the University Medical Center, Johannes Gutenberg UniversityBiopharmaceutical New Technologies (BioNTech) CorporationResearch Center for Immunotherapy (FZI) Email author 

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Cancer accumulates 10s to 1000s of genomic mutations of which a fraction is immunogenic and may serve as an Achilles’ heel of tumor cells. Mutation-specific T cells can recognize these antigens and destroy malignant cells. Strategies to immunotherapeutically address individual tumor mutations employing peptide or mRNA based vaccines are now actively investigated in mice and humans. An important step of determining the therapeutic potential of a mutanome vaccine is the detection of mutation reactive T-cell responses. In this chapter we provide protocols to identify and subtype mutation specific T cells in mice based on IFN-γ ELISpot and flow cytometry.

Keywords

mRNA Neo-epitopes Detection and subtyping of CD4+ and CD8+ T-cell responses